These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23604227)

  • 21. Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia.
    McMaster ML; Kristinsson SY; Turesson I; Björkholm M; Landgren O
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):19-22. PubMed ID: 19362963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia.
    Kyle RA; Benson J; Larson D; Therneau T; Dispenzieri A; Melton Iii LJ; Rajkumar SV
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):17-8. PubMed ID: 19362962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
    Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
    Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
    Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell cycle analysis of Waldenstrom's macroglobulinemia.
    Ocio EM; Mateo G; Vidriales B; Lopez-Berges MC; Garcia-Sanz R; Hernandez JM; Orfao A; San Miguel JF
    Clin Lymphoma; 2005 Mar; 5(4):250-2. PubMed ID: 15794858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.
    Schmidt K; Sack U; Graf R; Winkler W; Popp O; Mertins P; Sommermann T; Kocks C; Rajewsky K
    Front Immunol; 2020; 11():602868. PubMed ID: 33343574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
    Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.
    Zou H; Yang R; Liao ZX; Qin TD; Chen P; Zhang BY; Cao YP; Huang HF
    J Clin Lab Anal; 2019 Mar; 33(3):e22827. PubMed ID: 30485557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
    Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
    Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy.
    Al-Zuhairy A; Schrøder HD; Plesner T; Abildgaard N; Sindrup SH
    J Neurol Sci; 2015 Feb; 349(1-2):60-4. PubMed ID: 25582978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for transformation in asymptomatic immunoglobulin m monoclonal gammopathies.
    Morra E; Cesana C; Klersy C; Barbarano L; Miqueleiz S; Varettoni M; Lucchesini C; Ricci F; Lazzarino M
    Clin Lymphoma; 2005 Mar; 5(4):265-9. PubMed ID: 15794862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IgM myeloma and Waldenstrom's macroglobulinemia: a distinct clinical feature, histology, immunophenotype, and chromosomal abnormality.
    Chehal A; Taher A; Shamseddine A
    Clin Lab Haematol; 2003 Jun; 25(3):187-90. PubMed ID: 12755797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
    Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
    Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Origin of Waldenstrom's macroglobulinaemia.
    García-Sanz R; Jiménez C; Puig N; Paiva B; Gutiérrez NC; Rodríguez-Otero P; Almeida J; San Miguel J; Orfão A; González M; Pérez-Andrés M
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):136-147. PubMed ID: 27825459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.
    Schuster SR; Rajkumar SV; Dispenzieri A; Morice W; Aspitia AM; Ansell S; Kyle R; Mikhael J
    Am J Hematol; 2010 Nov; 85(11):853-5. PubMed ID: 20842638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.